ベータペプチドおよびその構成部分の溶液構造:アミロイド堆積と関連
1Suntory Institute for Bioorganic Research, Osaka, Japan.
まとめ
アルツハイマー病のアミロイドペプチド (1-42) と (1-39) は,異なるpHでアルファヘリコ構造を形成する. 中間pHはベータ構造を誘導し,pHの変化がアミロイドプラーク形成とベータペプチドの自己組み立ての鍵であることを示唆しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 構造生物学 構造生物学とは
- 神経科学は神経科学である.
背景:
- アルツハイマー病は,主にアミロイドβ (Aβ) ペプチドで構成されるアミロイド斑によって特徴付けられます.
- Aβ (1-42) はプラークコアに存在し,より溶解性の高いAβ (1-39) は脳血管アミロイドに存在します.
- 溶液中のAβペプチドの構造的性質は,アミロイド形成を理解するために重要である.
研究 の 目的:
- 合成および自然に発生するアミロイドβペプチド (Aβ) と溶液中の断片の二次構造を調査する.
- Aβペプチドの自己組み立てと構造的移行におけるpHと特定のペプチドセグメントの役割を明らかにする.
主な方法:
- 二次構造を分析するために,円形の二重化 (CD) スペクトロスコーピーを用いる.
- 詳細な構造分析のための二次元核磁気共鳴 (2D NMR) スペクトロスコピー.
- 様々なpHレベル,溶媒,温度で実施された研究.
主要な成果:
- Aβ (1-28),Aβ (1-39),Aβ (1-42) ペプチドは,低 pH と高 pH で単体アルファヘリル構造を採用しています.
- 中間pH (4-7) では,これらのペプチドは主にオリゴメリックβ構造を形成し,アミロイドプラークに見られるものと似ています.
- 排水性カルボキシル末端セグメントであるAβ (29-42) は,オリゴメールベータシートを独占的に形成し,Aβ (1-42) の折り畳みを指向する役割を示しています.
結論:
- アミロイドβペプチドは本質的に不溶性ではなく,pHの変化が自己組織化と堆積に不可欠である.
- 局所的または年齢に関連するpHの変化は,アミロイドプラークの形成を誘発する可能性があります.
- Aβ (29-42) セグメントは,アミロイドプラークの特徴であるベータプレートシート構造の重要な決定因子です.
さらに関連する動画
09:43Study of Short Peptide Adsorption on Solution Dispersed Inorganic Nanoparticles Using Depletion Method
Published on: April 11, 2020
07:20Discovery and Synthesis Optimization of Isoreticular Al(III) Phosphonate-Based Metal-Organic Framework Compounds Using High-Throughput Methods
Published on: October 6, 2023
関連する概念動画
Factors Affecting Solubility
Compared with pure water, the solubility of an ionic compound is less in aqueous solutions containing a common ion (one also produced by dissolution of the ionic compound). This is an example of a phenomenon known as the common ion effect, which is a consequence of the law of mass action that may be explained using Le Chȃtelier’s principle. Consider the dissolution of silver iodide:
EDTA: Auxiliary Complexing Reagents
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
Colloidal precipitates
The high insolubility of some precipitates can result in an unfavorable relative supersaturation. This can lead to colloidal particles with a large surface-to-mass ratio, where adsorption is promoted. For instance, in the precipitation of silver chloride, silver ions are adsorbed on the surface of the colloidal particles, forming a primary layer. This layer attracts ions of opposite charge (such as nitrate ions), forming a diffuse secondary layer of adsorbed ions. This electric double layer...
Micelles
Micelle formation is an intricate process that hinges on the properties of amphiphilic or amphipathic molecules and the conditions of the system in which they are found. Amphiphilic molecules, which have both hydrophilic (water-attracting) and hydrophobic (water-repelling) parts, play a critical role in this process.In aqueous environments, these molecules arrange themselves such that their hydrophilic heads are turned towards the water phase, while their hydrophobic tails are oriented away...
Retarders
Retarders are chemical admixtures designed to extend the setting time, which is especially useful when there is a delay in sequential concrete pours to prevent cold joints and to achieve a cohesive structure. Retarders, when used in appropriate amounts, can also enhance the architectural appearance of exposed aggregate finishes.
The function of retarders is to delay the setting of concrete, and this effect can be measured using a penetration test. The retardation process involves adding...
The function of retarders is to delay the setting of concrete, and this effect can be measured using a penetration test. The retardation process involves adding...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
